Coronary & Peripheral Stent Recalls: Boston Scientific, Abbott & Medtronic Teardown

Across the FDA's regulatory framework, intravascular stents represent some of the highest-stakes Class III medical devices. When an interventional cardiologist or vascular surgeon deploys a drug-eluting stent (DES) or a self-expanding peripheral scaffold, they rely on a flawless mechanical sequence: smooth delivery system tracking, precise balloon expansion or self-expanding sheath retraction, and stable placement. Any failure in this sequence can result in immediate thrombosis, vessel dissection, emergency coronary artery bypass grafting (CABG), or patient death.

For clinical engineers, healthcare procurement professionals, and regulatory affairs leads, understanding the post-market safety profile of these devices requires looking beyond individual manufacturer recall notices. This deep dive provides a manufacturer-spanning synthesis of FDA recalls and adverse-event reports from the Manufacturer and User Facility Device Experience (MAUDE) database for coronary and peripheral vascular stents.

Executive Summary: The Stent Safety Profile

• Recall Volume & Manufacturer Distribution: FDA records 131 device recalls across the coronary, peripheral, and iliac stent product-code set. Boston Scientific dominates the historical recall record with 81 of 131 recalls (61.8%), driven by a massive, design-related recall cluster in 2011 (73 recalls).
• MAUDE Signal Acuity: Stents generate a significant safety signal, with roughly 5,000 to 5,700 adverse event reports filed annually.
  • In 2024, MAUDE recorded 5,707 reports including 3,055 malfunctions, 2,442 patient injuries, and 208 deaths.
  • In 2025, MAUDE recorded 5,063 reports including 2,872 malfunctions, 1,960 patient injuries, and 228 deaths.
• Common Root Causes: The leading cause of official FDA stent recalls is Device Design (75 recalls), followed by process control failures and packaging design errors. In MAUDE, delivery-system malfunctions (resistance, balloon rupture, premature deployment) outnumber stent scaffold fractures.
• Freshest Event Anchors:
  • July 2025 Class I Recall: The Boston Scientific Carotid WALLSTENT Monorail Endoprosthesis was recalled due to delivery-system withdrawal resistance (6 cases, 0 deaths).
  • 2026 High-Acuity Event: The Terumo Relay Pro Thoracic Stent-Graft System (Bolton Medical / Terumo Aortic) deployment failures were linked to 3 patient deaths; the FDA issued an Early Alert in April 2026, and Terumo expanded the recall globally on July 1, 2026.
• Strategic Takeaway: While recall notices target specific lots, active MAUDE monitoring reveals that delivery-system issues represent a continuous clinical risk across all major brands. Cath-lab programs must integrate MAUDE tracking into their capital-procurement and risk-management workflows.

Stent Product Codes and Regulatory Classification

The FDA regulates coronary and peripheral stents under different product codes, depending on their technology (drug-eluting, bare metal, self-expanding, or balloon-expandable), anatomical location, and clinical indication. Almost all permanent coronary implants are classified as Class III devices subject to Premarket Approval (PMA), while peripheral and temporary stents range from Class II to Class III.

Below is the regulatory matrix for the primary stent and stent-graft codes analyzed in this teardown:

Note: Permanent coronary and peripheral stent scaffolds (NIQ, MAF, PNY, NIU, NIP, PRL, QWM, QWN) are Class III premarket-approval (PMA) devices. Covered and neurovascular stents (NIV, NJE) reached the U.S. market through the Humanitarian Device Exemption (HDE) pathway. SEU is the only Class II, 510(k)-cleared code in this set (21 CFR 870.5110). For post-market analysis, adjacent product codes such as aortic stent-grafts (governed by separate codes but overlapping in vascular delivery failure modes) are referenced to contextualize clinical deployment risks.

FDA Recall Volume and Manufacturer Distribution

An evaluation of the FDA recall database reveals 131 total stent recalls since the inception of the modern database. When categorized by the recalling firm, the data shows an extreme concentration of recall activity.

Recalls by Recalling Firm

Recalls by Year: The 2011 Boston Scientific Cluster

Reviewing the distribution of recalls over time shows that stent recall events are highly episodic rather than evenly distributed. The year-by-year trend is marked by a massive peak in 2011:

Year   Recall Count
2003   [██████████] 10
2004   [███] 3
2005   [███] 3
2007   [█] 1
2008   [███] 3
2009   [███████] 7
2010   [██] 2
2011   [█████████████████████████████████████████████████████████████████████████] 73
2013   [████████] 8
2014   [█] 1
2016   [██] 2
2017   [█████] 5
2018   [█] 1
2019   [███] 3
2020   [█] 1
2021   [██] 2
2022   [█] 1
2023   [██] 2
2024   [███] 3

In 2011, 73 recalls were initiated, almost all associated with Boston Scientific. This spike represents a single, multi-lot design-related action involving their coronary stent delivery systems, where balloon-deflation and catheter-withdrawal issues across several product lines forced a comprehensive corrective action.

Aside from this historical cluster, the baseline rate of stent recalls is low—typically averaging 1 to 5 recall events per year. However, because each single recall can represent thousands of distributed implants (and millions of dollars in clinical liabilities), the operational impact remains substantial.

Root Causes of Stent Recalls

To prevent future recall events, medical device QMS teams must look at the specific failure mechanisms identified by the FDA. When classifying the root causes of all 131 stent recalls, the data splits as follows:

1. Device Design (75 recalls): Cath-lab clinical teams frequently face delivery system failures, such as catheter shafts coiled or kinked during tracking, balloon inflation ports blocked by manufacturing residues, or self-expanding stent sheaths that retract prematurely. In coronary applications, design flaws often manifest as the stent slipping off the delivery balloon during placement through calcified or tortuous vessels.
2. Other / Undetermined (20 recalls): Lot-specific contamination, labeling mistakes, or mechanical tolerance stackups identified during internal investigations.
3. Process Control (11 recalls): Failures during manufacturing, including laser-welding defects in the delivery catheter tip, uneven polymer spraying on drug-eluting stents (leading to drug-load variations), or inadequate crimping of the stent scaffold onto the balloon.
4. Package Design / Material Selection (6 recalls): Sterile barrier breaches. If a stent's pouch seal fails during transport, the implant's sterility is compromised, which can lead to severe bloodstream infections or endocarditis.

QMS and Manufacturing Quality Systems Implications (21 CFR Part 820)

For manufacturers of vascular implants, the concentration of recalls in the Device Design and Process Control categories highlights critical vulnerabilities in Quality Management Systems (QMS) under 21 CFR Part 820.

Design Verification vs. Design Validation (21 CFR 820.30)

• Verification (Does the device meet specifications?): Stent delivery catheters are subjected to strict benchtop testing, including trackability, pushability, and crossability through tortuous glass models. However, benchtop models often fail to simulate the high-friction environment of calcified carotid or femoral arteries. If design verification fails to test the upper tolerance limits of shaft friction and catheter-withdrawal force (illustrated by the 2025 WALLSTENT withdrawal-resistance recall), the delivery system may bind in clinical use.
• Validation (Does the device meet user needs and clinical intent?): Design validation must involve realistic animal models or clinical trials that simulate worst-case scenarios, such as calcified bifurcations. Manufacturers must validate that delivery systems can be safely withdrawn even if balloon deflation is delayed.

Process Validation (21 CFR 820.75) and Crimping Control

The crimping of a coronary or SFA stent onto a delivery balloon is a highly critical process step that cannot be fully verified by non-destructive inspection. Therefore, the crimping process must be validated with high statistical confidence (e.g., 95% confidence / 99% reliability). If crimping parameters (temperature, pressure, dwell time) drift, the stent may lose its retention force. If the stent dislodges in a coronary artery, the operator is forced to deploy a retrieval loop or snare, converting a standard percutaneous coronary intervention (PCI) into an acute surgical emergency.

Detailed Root Cause Analysis: Mechanical Failure Modes

To support clinical decision-making, it is essential to distinguish between the primary mechanical failure modes that occur during stent delivery and deployment:

1. Delivery-System Withdrawal Resistance

This failure occurs when the inner lumen of the delivery catheter is undersized or becomes pinched during tracking. When the physician attempts to pull the delivery system back after deploying a self-expanding stent, the catheter binds against the guidewire or the stent's deployment sleeve. Forcing catheter retraction can lead to:

• Vessel Spasm or Dissection: The tension on the catheter is transferred directly to the arterial wall.
• Catheter Shear / Embolization: The distal tip of the delivery system can fracture, leaving foreign plastic material in the carotid or coronary circulation.

2. Balloon Inflation Failure and Delayed Deflation

Balloon-expandable stents require rapid balloon inflation and deflation. Failure to inflate is typically caused by a blockage in the inflation lumen (e.g., polymer residue or laser-welding flash). Delayed deflation is often caused by:

• Kinking of the Catheter Shaft: High tortuosity pinches the inflation lumen.
• Contrast Media Viscosity: Using highly concentrated contrast agents increases fluid resistance, delaying fluid withdrawal.
• Clinical Risk: During balloon inflation, coronary blood flow is completely occluded. Delayed deflation beyond 30–60 seconds leads to acute myocardial ischemia, severe angina, arrhythmias, or cardiogenic shock.

3. Stent Dislodgement (Pre-Deployment)

If the crimping force is insufficient or the stent is pushed against a calcified lesion, the stent can slide backward off the balloon. If this occurs before the guidewire is crossed, the stent becomes a free-floating embolus in the ascending aorta or coronary tree, requiring emergency retrieval or open surgical extraction.

MAUDE Adverse Events Deep Dive

While official FDA recall notices focus on specific manufacturing runs, the MAUDE database provides a continuous, real-time look at device performance in the field. Filtering the millions of MAUDE records for the primary stent product codes (MAF, NIQ, PNY, NIV, NIP, NIU, PRL, NJE, SEU, QWM, QWN) reveals the true volume of safety events.

Annual MAUDE Stent Report Volumes (2024 vs. 2025)

In 2024 and 2025, stents generated a massive adverse event footprint. Crucially, the "event_type" field indicates that more than 35% of these events involve patient injury or death:

Top Reporting Manufacturers in MAUDE (2024)

Analyzing the manufacturer field in the 2024 MAUDE dataset reveals which brands dominate the clinical adverse-event record:

1. Boston Scientific Corporation: 1,341 reports (MAF, NIQ, NIV, PRL). The Synergy DES line and Wallstent self-expanding lines represent the majority of these reports, reflecting both their large market share and their product mix.
2. Abbott Vascular: 742 reports (plus 611 reports under Abbott Vascular Inc., totaling 1,353 reports). Primarily driven by the Xience family of coronary drug-eluting stents, the market leader in coronary DES.
3. Medtronic Ireland / Medtronic: 647 reports. Primarily driven by the Resolute Onyx and Resolute Integrity coronary DES families.
4. Medos International SARL (Johnson & Johnson / Cordis legacy): 750 reports in 2025, showing significant post-market tracking for peripheral and carotid lines.

Critical Database Limitations

When analyzing this data, QMS and clinical teams must account for two major limitations in the FDA's datasets:

1. Empty Product Codes in Enforcement Reports: The FDA's enforcement.csv dataset frequently leaves the product_code column blank. This means that teams cannot run a simple database join to compile a list of Class I, II, or III recalls by product code. Instead, teams must manually search the description fields or consult the FDA's online Medical Device Recalls database.
2. MAUDE Patient Problem Parsing: The patient_problems column in MAUDE CSV files is notoriously difficult to parse programmatically due to embedded commas, quotes, and inconsistent terminology. To establish reliable safety baselines, researchers should use the event_type column (Death, Injury, Malfunction) rather than relying on unstructured patient-problem codes.

High-Acuity Case Studies (2025–2026)

To understand how these post-market failures impact clinical operations, we must examine two major high-acuity events from the 2025-2026 period.

1. July 2025: Boston Scientific Carotid WALLSTENT Monorail Class I Recall

On July 7, 2025, Boston Scientific issued an Urgent Medical Device Removal letter to hospitals, which the FDA posted as a Class I Recall on July 29, 2025.

• The Device: The Carotid WALLSTENT Monorail Endoprosthesis (self-expanding stent used to treat carotid artery stenosis).
• The Failure Mode: A manufacturing defect in the delivery catheter created excessive resistance during delivery-system withdrawal. When clinicians attempted to deploy the stent, the delivery catheter would bind, preventing smooth release or catheter removal.
• Clinical Impact: Across the recalled lots, 6 clinical cases required secondary catheter intervention to safely extract the trapped delivery system. While 0 patient deaths were reported, delivery catheter entrapment in the carotid artery carries an extreme risk of stroke, arterial dissection, or acute thrombosis.

Delivery Catheter Bound (Manufacturing Defect)
  [Cath Lab Insertion] ──> [Resistance on Withdrawal] ──> [Delivery Catheter Trapped]
                                                                  │
                                                                  └───> Emergency Retrieval Required (Stroke Risk)

2. 2026: Terumo Relay Pro Thoracic Stent-Graft System Event

In April 2026, the FDA issued an Early Alert after the Terumo Relay Pro Thoracic Stent-Graft System (originally developed by Bolton Medical, now part of Terumo Aortic) was linked to deployment failures in which the delivery system could not be separated from the deployed graft. Terumo initiated a voluntary recall in Japan on June 1, 2026 and expanded it globally on July 1, 2026, covering roughly 7,000 units distributed between May 2024 and March 2026.

• The Device: A large-profile thoracic aortic stent-graft delivery system used for the endovascular treatment of thoracic aortic aneurysms and dissections.
• The Failure Mode: The proximal clasp that releases the graft disconnected from the outer control tube, so the graft could not unclasp from the delivery system and the system could not be withdrawn from the patient as intended.
• Clinical Impact: As of April 23, 2026, three of four reported cases resulted in patient death — one from aortic perforation and two from conversion to open surgery that ended in fatal stroke. Because the aorta carries the body's primary blood supply, any delay or entrapment in this vessel is immediately life-threatening.
• Regulatory Frame: Aortic stent-grafts are classified under separate product codes from coronary DES, but this event illustrates how delivery-system mechanics — rather than the implantable scaffold itself — remain the primary source of high-acuity post-market failures in vascular medicine.

Sibling Device Comparison: Stents vs. Pacemakers vs. Joint Implants

To put the stent recall and MAUDE data in perspective, we can compare it to other Class III implantable devices we have analyzed, including the pacemaker and ICD lead recall teardown and the orthopedic joint replacement recall analysis:

Actionable Cath-Lab and Regulatory Recommendations

Based on this post-market surveillance data, clinical engineering and hospital procurement teams should implement the following steps:

1. Establish a Delivery-System Friction Protocol: Since delivery-system resistance is the leading cause of both the 2025 WALLSTENT Class I recall and the 2026 Terumo Relay Pro failures, cath-lab operators should immediately halt deployment if they encounter unexpected resistance during tracking. Do not attempt to force the catheter, as this often leads to delivery catheter kinking or entrapment.
2. Monitor MAUDE by Product Code: Do not rely solely on official Class I recall letters, which often take months to compile. Monitor MAUDE monthly for product codes NIQ, MAF, and NIU, looking for sudden spikes in "delivery system malfunction" or "balloon rupture" for your primary stent lines.
3. Reconcile Manufacturer Name Variants: When reviewing internal inventory or clinical registries against FDA recall lists, ensure you search for historical corporate names. Over the recall window, Abbott acquired Guidant, Physio-Control merged with Stryker, and Covidien/Valleylab was integrated into Medtronic.
4. Enforce Storage Temp Controls: Stent polymer coatings and delivery system balloons are sensitive to temperature and humidity. Verify that your cath-lab storage facilities maintain continuous temperature logging to prevent polymer degradation or balloon embrittlement, which can lead to premature rupture or drug-eluting layer peeling.
5. Standardize Contrast Media Dilution: Cath-lab programs should establish standardized protocols for contrast media dilution (e.g., 50/50 saline to contrast ratio) when inflating stent delivery balloons. This reduces contrast viscosity and lowers the risk of delayed balloon deflation in long, tortuous lesions.

Frequently Asked Questions

Has any coronary drug-eluting stent been recalled as Class I?

Yes. The FDA has issued multiple Class I designations for coronary drug-eluting stents. The most common causes are balloon-delivery catheter malfunctions (e.g., the stent slipping off the balloon during tracking, or the balloon failing to deflate after stent expansion), rather than defects in the drug-polymer scaffold itself.

How many deaths and injuries are reported in MAUDE for coronary stents each year?

MAUDE records approximately 200 to 230 deaths and 1,900 to 2,400 patient injuries annually associated with vascular stents. These numbers represent reported events; they do not establish a direct causal link for every patient, but they serve as a critical post-market safety signal.

What is the Boston Scientific Carotid WALLSTENT recall, and is it still active?

The July 2025 Class I recall targeted specific lots of the Carotid WALLSTENT Monorail Endoprosthesis due to delivery-system withdrawal resistance. Recalled inventory has been removed from hospital shelves, but clinical teams must remain vigilant when using similar self-expanding delivery systems.

What failed with the Terumo Relay Pro stent graft in 2026?

The delivery system could not be separated from the deployed graft — a proximal clasp disconnected from the outer control tube — so the system could not be withdrawn from the patient. The FDA issued an Early Alert in April 2026, and the event was linked to 3 patient deaths, highlighting the high risk associated with large-profile endovascular delivery systems.

Are peripheral (iliac/SFA) stents recalled as often as coronary stents?

No. Coronary stents are implanted in much higher volumes and face tighter anatomical constraints (coronary artery diameters of 2.5 to 4.0 mm vs. SFA diameters of 5 to 7 mm), which drives more frequent product design revisions and higher reporting volumes. However, peripheral stents still carry significant recall liabilities, particularly for self-expanding designs and stent-grafts.